Results 161 to 170 of about 5,445 (182)

In Vitro P-Glycoprotein Interactions and Steady-State Pharmacokinetic Interactions Between Tolvaptan and Digoxin in Healthy Subjects

Journal of Clinical Pharmacology, 2011
Susan E Shoaf, Masayuki Furukawa, Patricia Bricmont   +2 more
exaly  

Mechanisms of tolvaptan-induced toxicity in HepG2 cells

Biochemical Pharmacology, 2015
Yuanfeng Wu, Frederick A Béland, Si Chen   +2 more
exaly  

Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non‐peptide AVP antagonist in healthy subjects

British Journal of Clinical Pharmacology, 2012
Susan E Shoaf, Patricia Bricmont, Suresh Mallikaarjun   +2 more
exaly  

Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease

Drugs, 2015
Hannah A Blair, Blair Hannah A
exaly  

Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database

Drug Safety, 2015
Paul B Watkins, James H Lewis, David H Alpers   +2 more
exaly  

Tolvaptan, an Orally Active Vasopressin V2‐Receptor Antagonist—Pharmacology and Clinical Trials

Cardiovascular Drug Reviews, 2007
Hiroyuki Fujiki, Yoshitaka Yamamura, Toyoki Mori   +2 more
exaly  

Phase III Clinical Pharmacology Study of Tolvaptan

Cardiovascular Drugs and Therapy, 2011
Ａｔｓｕｓｈｉ Hirayama, Inomata Takayuki, Izumi Tohru   +2 more
exaly  

Tolvaptan

Reactions Weekly, 2012
openaire   +1 more source

Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors

Toxicological Sciences, 2017
William J Brock, Rachel J Church, Scott Q Siler   +2 more
exaly  

The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial

Clinical and Experimental Nephrology, 2015
Satoru Muto, Haruna Kawano, Eiji Higashihara   +2 more
exaly